Breaking News on Global Pharmaceutical Technology & Manufacturing

Drug Delivery: Top Headlines

Echo's cannabis API delivery formulation could aid low solubility drugs

Echo is investigating its delivery tech, Alitra, on its cannabis-based candidates

30-Jul-2015 - A drug delivery platform which increased the bioavailability of a cannabis-based drug candidate 30% could be used to boost solubility of other APIs, says Echo Pharmaceuticals.

Related news

News in brief

Sanofi Q2 Afrezza sales far from a giant leap for MannKind

30-Jul-2015 - The €3m Afrezza has contributed to Sanofi’s revenues since launch is unlikely to subdue growing concerns from commentators surrounding its partner MannKind which developed the inhalable insulin.

EMD Millipore and celares team to offer PEGylation to biologic makers

29-Jul-2015 - Attaching PEG-chains to biological molecules can increase bioavailability and speed up development of protein-based therapies and biosimilars, says EMD Millipore which has inked a deal with PEGylation firm celares.

Hikma buys B-I generics subsidiary, strengthens position in US market

28-Jul-2015 - Hikma says its $2.65bn acquisition of Roxane Laboratories will make it the sixth largest firm in the US generics space.

Capsugel expanding Encap plant on rising HPAPI demand

23-Jul-2015 - Capsugel is doubling the size of a facility in Scotland to support demand for the encapsulating of drugs containing high-potency active pharmaceutical ingredients (HPAPIs).

West scaling up AZ plant on demand for Smartdose wearable injector

21-Jul-2015 - Demand for West’s wearable injector - which uses the recently-approved Crystal Zenith delivery system - has led to the expansion of a facility in Arizona.

Planes, drones but no automobiles: NASA pilots pilotless plane for drug delivery

20-Jul-2015 - NASA has used a remote control plane and a fleet of drones to deliver drugs in an approach that could help pharma firms get medicines to patients in hard to reach locations.

Celgene boosting immune-inflammatory presence with $7.2bn Receptos deal

16-Jul-2015 - Celgene has shelled out $7.2bn (€6.6bn) to acquire Receptos which is developing an oral lymphocyte trafficking agent for multiple sclerosis and inflammatory bowel disorder.

Drug Delivery: Featured news

Key Industry Events


Access all events listing

Our events, Shows & Conferences...